EMERGE ARK GENOMICS & BIOTECH ETF

Ticker: EAGB

Join our live conversations with ARK’s leading analysts and an innovation review with Catherine Wood (CEO/CIO, ARK Invest).

Investment Objectives

EAGB is an actively managed exchange-traded fund (ETF) that seeks to achieve long-term growth of capital by investing primarily, under normal circumstances, in the global equity securities of companies that are, or are expected to be, focused on extending and enhancing the quality of human and other life through technological and scientific developments, improvements and advancements in biotech and genomics

Profile of an Innovator : Portfolio Manager

Catherine Wood founded ARK Investment Management in 2014. She spent the previous 12 years at Alliance Bernstein as Chief Investment Officer of Global Thematic Strategies that had over US$5 billion in assets under management. Before AllianceBernstein, she worked for 18 years with Jennison Associates as Chief Economist, Equity Research Analyst, Portfolio Manager and Director. Catherine started her career in Los Angeles at the Capital Group as an Assistant Economist.

Why Invest?

Exposure to Innovation: Aims to achieve thematic multi-capitalization exposure to innovation across sectors. ARK believes the securities held in EARK present the best risk-reward opportunities from ARK’s innovation-based themes.

Growth Potential: Aims to capture long-term growth with low correlation of relative returns to traditional growth strategies and negative correlation to value strategies.

Tool for Diversification: Active stock selection results in little overlap with traditional indices. EAGB can be a complement to traditional value/growth strategies.

Grounded in Research: Combines top-down and bottom-up research in its portfolio management to identify innovative companies and convergence across markets.

Cost Effective: Provides a lower-cost alternative to mutual funds with true active management in an ETF that invests in rapidly moving themes.

Top 10 Holdings

As at May 31, 2021

Teladoc Health Inc.7.04%
EXACT Sciences Corportation5.05%
CareDX4.34%
Pacific Biosciences of California Inc.4.21%
Regeneron Pharmaceuticals Inc.4.12%
Vertex Pharmaceuticals Inc.3.71%
Novartis AG3.62%
Fate Therapeutics Inc.3.58%
Ionis Pharmaceuticals Inc.3.51%
Twist Bioscience Corporation3.50%
Click Here to Download EAGB Full Holdings Report as at May 31, 2021

Fund Facts

EAGB NAV (As at June 10, 2021): $22.55

EAGB.U NAV (As at June 10, 2021): $18.64

CUSIP CAD Series: 291004109
CUSIP USD Series: 291004208
TICKER: EAGB
INCEPTION DATE: 7.29.2019
EXCHANGE: NEO Stock Exchange
MANAGEMENT FEE: 0.80%
CURRENCY: CAD/USD
SUB-ADVISORS: ARK Investment Management LLC

FEES
Management Fee:0.80%
MER:1.15%*

*as expected for 2021, please reference emergecm.ca for information regarding the MER for each ETF.

Fund Characteristics

As at May 31, 2021

  • Americas 86.4%
  • Europe 9.5%
  • Asia 3.3%
  • Middle East 0.6%
Sector Allocation

As at May 31, 2021

  • Health Care 96.5%
  • Information Technology 2.2%
  • Financials 1.2%

Commissions, management fees, brokerage fees, and expenses may be associated with an investment in ETFs. Before investing, you should carefully consider the ETF’s investment objectives, strategies, risks, charges, and expenses. This and other information are in the ETF’s prospectus, which may be obtained by visiting www.emergecm.ca or www.sedar.com. Please read the ETF prospectus carefully before you invest. An investment in an ETF is subject to risks and you can lose money on your investment. Detailed information regarding the specific risks of the ETF can be found in the prospectus. There can be no assurance that the ETF will achieve its investment objective. The ETF’s portfolio is more volatile than broad market averages. Units of the ETF are bought and sold at market price and there can be no guarantee that an active trading market for the ETF units will develop or be maintained, or that their listing will continue or remain unchanged. ETFs are not guaranteed. Their values change frequently. Past performance may not be repeated. The statements contained in this document are based on information believed to be reliable and are provided for information purposes only. Where such information is based in whole or in part on information provided by third parties, we cannot guarantee that is accurate, complete or current at all times. This document does not provide investment, tax or legal advice, and is not an offer or solicitation to buy. Graphs and charts are used for illustrative purposes only and do not reflect future values or returns on investment. Particular investment strategies should be evaluated according to an investor’s investment objectives and tolerance for risk. Emerge Canada Inc. and related entities are not liable for any error or omission in the information or for any loss or damage suffered. Certain statements in this marketing profile include forward-looking statements, including, but not limited to, the launch of the Emerge ETF and those statement identified by the expressions “believe”, “will” and similar expressions to the extent they relate to the Emerge ETF, Emerge or the space exploration industry. These forward-looking statements are subject to a number of risks and uncertainties and are based on several assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from current expectations. Forward-looking statements are not guarantees of future results.